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Abstract: 
Study Design Nineteen dogs underwent L4-L5 intertransverse process fusions with either 58 μg, 115 
μg, 230 μg, 460 μg, or 920 μg of recombinant human bone morphogenetic protein-2 carried by a 
polylactic acid polymer. A previous study (12 dogs) compared 2300 μg of recombinant human bone 
morphogenetic protein-2, autogenous iliac bone, and carrier alone in this model. All fusions 
subsequently were compared. 
Objectives: To characterize the dose-response relationship of recombinant human bone 
morphogenetic protein-2 in a spinal fusion model. 
Summary of Background Data: Recombinant osteoinductive morphogens, such as recombinant human 
bone morphogenetic protein-2, are effective in vertebrate diaphyseal defect and spinal fusion models. 
It is hypothesized that the quality of spinal fusion produced with recombinant human bone 
morphogenetic protein-2, above a threshold dose, does not change with increasing amounts of 
inductive protein. 
Methods: After decortication of the posterior elements, the designated implants were placed along the 
intertransverse process space bilaterally. The fusion sites were evaluated after 3 months by computed 
tomography imaging, high-resolution radiography, manual testing, mechanical testing, and histologic 
analysis. 
Results: As in the study using 2300 μg of recombinant human bone morphogenetic protein-2, 
implantation of 58–920 μg of recombinant human bone morphogenetic protein-2 successfully resulted 
in intertransverse process fusion in the dog by 3 months. This had not occurred in animals containing 
autograft or carrier alone. The cross-sectional area of the fusion mass and mechanical stiffness of the 
L4-L5 intersegment were not dose-dependent. Histologic findings varied but were not related to 
rhBMP-2 dose. Inflammatory reaction to the composite implant was proportional inversely to the 
volume of the fusion mass. 
Conclusions: No mechanical, radiographic, or histologic differences in the quality of intertransverse 
process fusion resulted from a 40-fold variation in dose of recombinant human bone morphogenetic 
protein-2. 
Recombinantly produced osteoinductive molecules, such as human bone morphogenetic protein, have 
facilitated healing of middiaphysial defects and fusion of spinal segments in lower vertebrates. Doses 
of recombinant bone morphogenetic proteins ranging from 1.4 μg to more than 2000 μg have been 
tested in experimentally produced segmental long bone defects in rodents, rabbits, sheep, and 
dogs.3,5,6,8,9,17,25 A recent study using recombinant human bone morphogenetic protein-7 (rhBMP-7) in 
a rabbit ulnar nonunion model suggested that greater amounts of implanted protein resulted in 
greater early bone formation and a faster rate of healing.5 However, radiographic findings by 8 weeks 
and histologic results by 12 weeks were similar in all ulnar defects implanted with doses above a 
threshold of 6.25 μg. All of these defects healed successfully, whereas ulnae implanted with less than 
the threshold amount of inductive protein failed to do so. 
The relationship between BMP dose and the rate and character of intersegmental spinal fusion has not 
been well defined. The purpose of this investigation was to evaluate fusion characteristics associated 
with a logarithmic series of doses of recombinant human bone morphogenetic protein-2 (rhBMP-2) 
delivered by a porous polylactic acid polymer in a dog lumbar intertransverse process fusion model. A 
previous study at this institution showed that a dose of 2300 μg of rhBMP-2 delivered by the same 
carrier was superior to autologous iliac crest bone graft for producing single-level lumbar arthrodesis.16 
Data from that study are included here for purposes of comparison. 
▪ Materials and Methods 
Design. Nineteen mature female beagles underwent L4-L5 intertransverse process fusions in this study 
(Table 1). Five doses of rhBMP-2 in a modified logarithmic schedule were tested. In a previous study 
with this model, five dogs were implanted with autogenous iliac crest graft, five were implanted with a 
2300 μg dose of rhBMP-2, and two were implanted with the carrier alone. The results from that study 
are included here for comparison. Neither internal fixation nor external immobilization was used in 
either investigation. All animals were killed 3 months after surgery. 
 Table 1 
 
Materials. The delivery vehicle open cell polylactic acid (OPLA) was prepared from D,D-L,L-polylactic 
acid and macrostructured into an “open cell” network of interconnected voids. The dimensions of this 
2.2-mL rectangular strip were 12.0 mm × 6.0 mm × 30.0 mm (supplied by Sofamor Danek, Memphis, 
TN; developed and manufactured by THM Biomedical, Minneapolis, MN). 
The rhBMP-2 (manufactured and supplied by Genetics Institute, Andover, MA) was provided in freeze-
dried form and reconstituted intraoperatively with sterile water. One milliliter of solution containing 58 
μg, 115 μg, 230 μg, 460 μg, or 920 μg of rhBMP-2 was added to each OPLA strip to produce the 
composite implant. 
Subjects. The animals were obtained from a single breeder and screened for systemic disease and 
conditioned for at least 1 week before inclusion in the study. 
Surgical Procedure. Under halothane anesthesia and endotracheal intubation, the posterior lumbar 
region was prepared in sterile fashion. Using a limited midline approach, the paraspinal musculature 
was retracted from the spinous processes, lamina, facet joints, and transverse processes. With the 
assistance of a localization radiograph, care was taken to avoid exposure of adjacent facet joints and 
transverse processes. The appropriate transverse processes, lamina, and facet joints were decorticated 
with a power burr (Dremel Moto- Tool, Model 395, Racine, WI) until punctate bleeding was observed. 
Osseous debris left by decortication was washed away thoroughly with copious irrigation. 
The composite implant was prepared by the surgical assistant and inserted by the surgeon, who was 
blinded to the condition of the implant. When autograft was used, tricortical portions of both iliac 
crests were harvested through the same incision and morselized to expose the cancellous surfaces. All 
implants were placed into the right and left posterolateral gutters in direct apposition to the 
decorticated transverse processes of L4 and L5. The implants were not in contact with the exposed 
lamina. 
Routine closure of the dorsolumbar fascia, subcutaneous tissue, and skin was performed. Parenteral 
antibiotics (enrofloxacin, 2.5 mg/kg, or cefazolin, 2.0 mg/kg) were administered intraoperatively and 
postoperatively for 72 hours after surgery. No postoperative dressings or braces were applied. The 
animals were allowed unrestricted activity. 
Computed Tomography Evaluation. With the animals under pentobarbital anesthesia (Nembutal, 
Abbott, Abbott Park, IL), computed tomography (CT) scans were obtained 2 and 3 months after surgery 
for all animals. Sections of the fusion site were graded qualitatively for bone formation and 
remodeling. Also, quantitative CT analysis was performed using a photo image analyzer (superfine 
pitch monitor, Image-1/AT software, University Imaging Corp., West Chester, PA) as follows: cross-
sectional bone area was measured in four specific axial images of the fusion site and in four 
anatomically matched axial images of the untreated L3 vertebral body. The axial images were selected 
based on known vertebral body landmarks consistently present in beagles. Estimation of new bone 
formation was accomplished by measuring the difference in cross-sectional bone area between images 
of the fusion site and images of anatomically corresponding sections of the L3 vertebral body 
(reference measures). The values were expressed as ratios to these reference measures. 
Sacrifice. Three months after surgery, the animals were killed with 0.22 mL/kg of Euth-6 Veterinary 
Solution (Western Medical Supply Company, Arcadia, CA), and the lumbar spines were explanted. 
Manual Testing. After explantation, the L4-L5 intervertebral segment was tested manually for motion. 
The intervertebral segment was graded a nonfusion if motion was detected in any plane. Absence of 
motion was considered sufficient evidence of fusion. 
High-Resolution Radiographic Evaluation. Using the Faxitron imaging device (Field Emission 
Corporation, McMinnville, Oregon), a high-resolution radiograph was taken of the explanted lumbar 
spine in the coronal plane after cleaning of soft tissues (Kodak Industrex Film, 50 - 13 × 18 cm, #507–
2392, exposure ≈30 MA @ 3 minutes). A radiographically successful intertransverse process fusion was 
defined as complete and uninterrupted osseous bridging of the transverse processes bilaterally. 
Unilateral osseous bridging or facet or interlaminar bony union was not considered successful 
intertransverse process fusion. 
Nondestructive Mechanical Testing. The mechanical tests were conducted on all but one specimen 
from each rhBMP-2 dose group. The testing consisted of manually applying pure torques and linear 
loads and then measuring the corresponding angular and linear displacements. The slope of the force-
displacement curve at 45 N of applied force was used to calculate the stiffness in each mode. The 
measurements were conducted in the following modes: flexion-extension (sagittal plane), right and left 
lateral bending (coronal plane), and clockwise and counterclockwise rotation (axial plane). For each 
mode, the average of the median measures of stiffness for the two directions was used for analysis. 
The protocol for this testing has been described previously.16  
Histologic Analysis. After mechanical testing, the spinal motion segment was fixed in 10% neutral 
buffered formaldehyde solution and bisected sagittally for histologic analysis. Both halves of the spinal 
segment were dehydrated sequentially in 70% alcohol for 2–3 days, 95% alcohol for 2–3 days, two 
changes of 100% alcohol for 2–3 days each, and xylene for 1 day. 
The explants then were embedded in methylmethacrylate and sectioned on a diamond saw (Buehler 
Isomet, Lake Bluff, IL) to produce at least 10 sections of an approximate thickness of 100–200 μm. One 
side of the bisected level was sectioned in the sagittal plane, whereas the other side was sectioned in 
the axial plane. This orientation was randomized. 
Undeclacified sections of the explants from this study were imaged with copper k-α-radiation at 20 kV 
and 30 mA using a microradiography unit (Kristalloflex-2, Siemens, New York, NY) and spectroscopic 
film (Kodak, Rochester, NY). Sections were exposed for 12.5 minutes for each 100 μm of thickness. 
These spectroscopic plates then were developed, fixed, and analyzed for ossification using standard 
optical microscopy. 
Staining was performed after microradiography to determine the quality and quantity of osteogenesis. 
When de novo bone was present, the distinct histogenesis (e.g., enchondral or intramembranous 
osteogenesis) was noted as was the presence of woven or lamellar bone matrix. Finally, differential 
staining with basic fuchsin and toluidine blue-o was used to evaluate the histologic and cytologic host 
response to the implant. This included evaluating the presence or absence of an inflammatory 
response to the carrier, the amount and quality of bone present, and the interface between the new 
bone and the native host bone. After staining, all undecalcified sections and microradiographs were 
read by an orthopedic histopathologist in a blinded fashion. 
Statistical Analysis. Qualitative manual testing data, radiographic data, and CT data were analyzed 
using Fisher's exact test. Analysis of variance (BMDP Statistical Software, 2 V, Los Angeles, CA) was 
applied to measures of stiffness. Group average stiffness was compared among rhBMP-2 doses (high 
vs. low) separately for each mode of motion: sagittal bending, coronal bending, and axial rotation. 
There was one grouping factor (dose of rhBMP-2). Pearson's correlation coefficient was used to 
characterize the relationships between variables of interest and dose of rhBMP-2. Logistic regression 
analysis was used to evaluate the relationship between radiographic fusion and dose of rhBMP-2 (SAS, 
Version 6, SAS Institute Inc., Cary, NC). 
Results 
Surgery 
All animals tolerated the procedures well, and no perioperative deaths occurred. Postoperative 
infections developed in two dogs that had been implanted with 58 μg of rhBMP-2, so they were 
excluded from the study. The dogs weighed between 8.60–12.50 kg (average, 10.49 kg) and ranged in 
age from 1.09 to 2.28 years (mean age, 1.59 years) at the time of surgery. 
Computed Tomography 
Computed tomography images showed new bone formation at all sites implanted with rhBMP-2 by 2 
months after surgery (Figure 1). There was scant evidence of peripheral cortices surrounding the fusion 
masses in any site by this time. There were no remarkable qualitative differences between specimens 
containing different doses of the inductive protein. 
 
Figure 1 
 
By 3 months, the presence of peripheral cortices was noted in several rhBMP-2 implanted sites (Figure 
2). This remodeling was not related to the dose of the inductive protein. 
 Figure 2 
 
Quantitative CT analysis measuring new bone formation was performed on all fusion sites containing 
rhBMP-2. The findings are summarized in Table 2 and include data from the previous study. There 
were no differences in cross-sectional area of new bone regardless of the dose of rhBMP-2 implanted 
(P = 0.84). 
 Table 2 
 
High-Resolution Radiography 
Using the strict criteria for fusion described previously, radiographic fusion rates are depicted in Table 
3. In the rhBMP-2 implanted sites, 14 (82%) of 17 sites in the current study were fused 
radiographically. Two failures were noted in the lowest two dose groups (58 μg and 115 μg) and the 
third was in an intermediate group (460 μg). All three of these spines actually were unilateral fusions 
but, according to the rating criteria, were considered failures. Using logistic regression analysis, 
however, no relationship was found between rhBMP-2 dose and radiographic fusion (P = 0.55; n = 17). 
Examples of highresolution radiographs of spines containing rhBMP-2 implants can be seen in Figure 3. 
 Table 3 
 
 
Figure 3 
 
Manual Testing 
All spines implanted with rhBMP-2 composites, regardless of dose, achieved solid intersegmental 
fusion by manual motion testing (Table 4). No differences could be detected among rhBMP-2-
implanted sites. 
 
Table 4 
 
Mechanical Testing 
Mechanical testing was performed on all specimens regardless of the presence or absence of 
intertransverse process bridging. This was done to incorporate effects of facet arthrodesis that have 
been reported in dog models after decortication.4 Median values for stiffness for each mode of testing 
were compared. There were no significant differences in mechanical stiffness among the dose groups 
of rhBMP-2 (sagittal bending, P = 0.38; coronal bending, P = 0.34; axial torque, P = 0.42). There was no 
correlation between dose and stiffness of fusion in any of the three planes of motion (sagittal bending, 
P = 0.99; coronal bending, P = 0.45; axial torque, P = 0.39). 
Histologic Examination 
Several specimens that had been implanted with the rhBMP-2 and OPLA carrier composite exhibited 
remnants of the polymeric delivery vehicle (Figure 4). The amount of undegraded polymer was not 
related to the dose of rhBMP-2 that was used. There appeared to be no relationship between the 
degree of inflammatory response and the dose of rhBMP-2. However, when abundant bone formation 
and a large fusion mass occurred, little to no inflammatory response was observed. When a large 
fusion mass did not occur, a low grade chronic inflammatory response consisting of multinucleated 
giant cells and round cells was observed. 
 
Figure 4 
 
Varying quantities of de novo bone were noted in all specimens containing rhBMP-2 (Figure 5). Grossly 
and microscopically, no intrusion of de novo bone was noted in the spinal canal. Lamellar and woven 
bone trabeculae were seen with scattered areas of cortical remodeling. The overall amount of de novo 
bone, the ratio of lamellar to woven bone, and the degree of cortical remodeling could not be 
correlated with the dose of rhBMP-2. There was as much qualitative difference in bone formation 
between animals containing the same dose as there was between animals containing different doses. 
 Figure 5 
 
▪ Discussion 
Bone morphogenetic protein constitutes less than 0.01% of total bone protein and less than 0.001% of 
the wet weight of marrow-free compact bone.19–21 Before the successful cloning and expression of 
recombinant forms of osteoinductive proteins, relatively large amounts of diaphysial cortical (compact) 
bone had been required to extract useful amounts of BMP-containing protein aggregates.18 For 
example, Wang et al22 estimated a yield of 20 μg of highly purified (300,000-fold) osteoinductive 
preparation per 10 kg of bovine bone, and because even highly purified fractions contain a mixture of 
osteogenic and nonosteogenic matrix proteins, accurate dose-response relationships had been difficult 
to ascertain. Further, osteogenic activity is known to be influenced by nonspecific and specific immune 
reactions to these protein aggregates. Thus, the relatively low activity of crude bone extracts had been 
attributed to immunogenic but nonosteogenic components of the extract.1  
The derivation and expression of cDNA clones of specific BMPs have permitted precise quantitation of 
the action of these molecules. Recombinantly produced protein preparations essentially contain 
singular molecular species (roughly 90% pure). Consequently, the measures of inductive protein 
contained within implants are more exact, and dose-response studies are more valid. Further, because 
members of the BMP family of proteins have been highly conserved (genetically consistent) for 
approximately 600 million years, they exhibit virtually no species specificity.8,24 Immunogenic 
influences on osteogenic activity, consequently, are minimal. Finally, because gene-cloning technology 
enables mass production of these proteins, evaluation of a broad spectrum of doses is feasible. 
Recent in vivo ectopic bone-forming assays have suggested that volume of early bone formation is 
related linearly to dose of recombinant BMP.23 However, efficacy studies in specific applied clinical 
models have not shown, above a defined threshold dose, that the rate or quality of clinical success is 
related to the actual dose.5  
In this study, all sites implanted with rhBMP-2 achieved clinical arthrodesis by 3 months after 
implantation. This was true despite a 40-fold variation between the highest and lowest doses tested. 
Compared with the results using autogenous iliac bone graft from the previous study (Tables 3,4), all 
rhBMP-2-containing implants were associated with clearly superior clinical and radiographic results 
(manual testing: all rhBMP-2 conditions greater than autograft, P < 0.001; radiographic testing: all 
rhBMP-2 conditions greater than autograft, P < 0.001). Even the lowest dose within this range was 
more effective than was iliac crest graft for generating intersegmental fusion within 3 months. 
Additional data from the authors' laboratory on two dogs have shown successful clinical fusion with 
autogenous iliac crest graft in this model when the animals were maintained for 6 months.15 It appears 
that successful intertransverse process fusions occur with autograft in this model, albeit not as rapidly 
as compared with rhBMP-2 implants. The differences were particularly significant at the 3-month 
timepoint. 
Of three dogs implanted with rhBMP-2 that did not satisfy strict radiographic criteria for fusion 
(bilateral intertransverse process bridging), two belonged to the lowest two dose groups. Both animals 
exhibited unilateral unions. These findings were not statistically significant, and moreover, when 
mechanically tested, the fusions obtained in these animals were neither different from other fusions 
within these groups nor from fusions obtained with higher doses of rhBMP-2. Combining the data from 
this study and previous data with this model, the authors cannot conclude that there are differences in 
the rates of clinical and radiographic fusion produced with 58–2300 μg doses of rhBMP-2 (manual 
testing, all fused; radiographic testing, P = 0.38). However, the presence of radiographic “failures” with 
the lowest doses suggests that the lower end of this range of doses may be approaching the minimum 
effective dose. This may be better elucidated with an increased sampling size at these lower doses. 
When characterizing the quality of fusion in terms of mechanical stability, no relationship was noted 
between fusion stiffness and rhBMP-2 dose in either sagittal, coronal, or axial planes of motion. When 
combined with previous data, still no significant relationship between fusion stiffness and dose was 
noted (sagittal bending, P = 0.48; coronal bending, P = 0.11; axial torque, P = 0.06). The data again were 
compared after mechanical testing results were reassigned to “high dose” (2300 μg), “low dose” (58–
920 μg), autograft, and carrier-only groups. The comparisons are summarized in Table 5. Both high-and 
low-dose rhBMP-2 sites had resultant fusions with greater stiffness than did autografted sites in all 
planes of motion (axial torque, P < 0.001, P < 0.001; sagittal bending, P < 0.02, P < 0.01; and coronal 
bending, P < 0.04, P < 0.02). High-dose implanted sites were not different from low-dose implanted 
sites in stiffness to sagittal and coronal bending (P = 0.42, P = 0.19). High-dose sites did exhibit greater 
stiffness to axial torque testing compared with low-dose sites (P = 0.03). However, because this was 
noted only in one plane of motion and a significant linear relationship was not observed when the 
doses were separated, the authors do not believe that these data confirm a qualitative difference in 
strength of fusion. Moreover, evidence that there were no differences in cross-sectional new bone 
formation between the different dose groups as determined by quantitative CT analysis further argues 
that the fusions were similar qualitatively. 
 
Table 5 
 
Histologically, abundant bone formation had been noted in all specimens containing the inductive 
protein. No overt qualitative differences in fusion mass associated with the current spectrum of doses 
could be detected. Rather vigorous bone formation was seen despite a low rhBMP-2 dose in some 
animals, whereas less bone formation was seen occasionally in high-dose implanted sites. In addition, 
there was no relationship between the degree of remodeling or the presence of remnant polymer, and 
the dose of the inductive protein. 
In the previous study, a chronic foreign body response consisting of multinucleated giant cells, 
histiocytes, and pyknotic mononuclear round cells was seen in sites that had been implanted with 
OPLA carrier only.16 In this study, a low-grade chronic inflammatory response also was noted in several 
specimens that contained OPLA with rhBMP-2 but was far less than the reaction observed when OPLA 
was used alone. Interestingly, the inflammatory response to the composite implant inversely was 
proportional to the abundance of the fusion mass and not to the dose of the rhBMP-2. It is possible 
that this is related to a limited population of inducible stem cells. Thus, rapid recruitment of stem cells 
to boneforming cells may limit the number of cells available for an inflammatory response. Conversely, 
the presence of an early inflammatory response may limit the number of stem cells available for 
osteoinduction, thereby altering subsequent osteogenesis. Stem cell lineage studies currently are in 
progress and may provide useful information in the near future. 
The events of the biologic response to rhBMP-2 in vivo are complex and may be influenced by several 
variables. The timecourse of activity of rhBMP-2 in the bone formation process, the location of its 
target cell, and its interactions with other growth factors are subjects of current research.11,12,18 
Certainly, the influence of the delivery vehicle cannot be overemphasized. Osteoinductive molecules 
such as rhBMP-2, when implanted alone, are cleared rapidly from the circulation and are ineffective. 
Lucas et al10 and other have suggested that optimal delivery of inductive proteins requires controlled 
release, adequate exposure of the protein to the inducible target cells, ease of ingrowth of host tissue 
into the carrier, biocompatibility of the carrier, and resorption or incorporation of the implant into 
newly formed bone. 
An open-cell polylactic acid polymer was used exclusively as the delivery vehicle in this study. The 
measured efficacy of rhBMP-2 in this model, consequently, is a reflection of this carrier's ability to 
satisfy the previously mentioned requirements. Biocompatibility of polylactic acid polymers has been 
of concern in previous studies,7,13,14 and the presence of an immune response could be expected to 
influence the activity of the inductive protein. A prominent foreign body reaction was noted in the 
previous study when the polymeric delivery vehicle was implanted alone and was subdued in this study 
when the carrier was combined with the osteoinductive protein. The effect of even the low-grade 
inflammatory processes on the osteoinductivity of rhBMP-2 is unresolved. A similar relation between 
efficacy and dose would not necessarily be observed if another delivery vehicle such as fibrillar 
collagen, insoluble noncollagenous protein, or biocompatible ceramic were used. This model currently 
is being used to investigate some of these alternative delivery vehicles. 
There is some evidence, although inconclusive, that more evolved animals may have a relative lack of 
inducible cells outside the skeleton.2 The activity of rhBMP-2 in nonhuman primates currently is the 
subject of considerable interest. In this regard, it remains to be seen whether dosing data gathered 
from lower vertebrate models such as this can be appropriately extrapolated for use in humans. 
Nonetheless, the intent of this investigation was to characterize the relation between dosage of 
rhBMP-2 and clinical efficacy in an applied spinal fusion model. Previous studies on long bone defects 
in lower vertebrate models have suggested that, above a minimal threshold dose, the clinical 
effectiveness of rhBMP-2 remains relatively consistent. In this study, the similarity of the fusions 
obtained across a 40-fold range of doses suggests that such a relationship may exist for dog spinal 
fusions. 
Conclusion 
Above a minimum threshold dose, fusions produced in lower vertebrates with recombinant 
osteoinductive morphogens, such as rhBMP-2, do not vary with increasing dose. Variables such as the 
delivery vehicle, surgical technique, and evolutionary status of the recipient may be more pertinent. 
Further studies examining these factors would be beneficial. 
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